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Abstract
Background—Both HIV and depression are associated with increased heart failure (HF) risk. 
Depression, a common comorbidity, may further increase the risk of HF among HIV+ adults. We 
assessed the association between HIV, depression and incident HF.
Methods and Results—Veterans Aging Cohort Study (VACS) participants free from 
cardiovascular disease at baseline (N = 81,427; 26,908 HIV+, 54,519 HIV-) were categorized into 
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four groups: HIV- without major depressive disorder (MDD) [reference]; HIV- with MDD; HIV+ 
without MDD; and HIV+ with MDD. ICD-9 codes from medical records were used to determine 
MDD and the primary outcome, HF. After 5.8 follow-up years, HF rates per 1000 person-years 
were highest among HIV+ participants with MDD (9.32; 95% CI, 8.20–10.6). In Cox proportional 
hazards models, HIV+ participants with MDD had significantly higher risk of HF [adjusted hazard 
ratio (aHR) = 1.68; 95% CI, 1.45–1.95] compared to HIV- participants without MDD. MDD was 
associated with HF in separate fully adjusted models for HIV- and HIV+ participants (aHR = 1.21; 
1.06–1.37 and 1.29; 1.11–1.51, respectively). Among those with MDD, baseline antidepressant 
use was associated with lower risk of incident HF events (aHR = 0.76; 0.58–0.99).
Conclusions—Our study is the first to suggest MDD is an independent risk factor for HF in 
HIV+ adults. These results reinforce the importance of identifying and managing MDD among 
HIV+ patients. Future studies must clarify mechanisms linking HIV, MDD, antidepressants, and 
HF; and identify interventions to reduce HF morbidity and mortality in those with both HIV and 
MDD.
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Introduction
Antiretroviral therapy (ART) and effective clinical management have resulted in improved 
life expectancy for adults with HIV infection (HIV+).1, 2 Yet, the risk for cardiovascular 
disease (CVD) is higher for HIV+ adults compared to those without HIV (HIV-).3 The risk 
of heart failure (HF) is significantly higher in HIV+ adults compared to HIV- adults who are 
similar in age, gender, and race/ethnicity.4–6
Poor mental health is an additional concern for HIV+ adults. Depression is common in the 
US with the general population facing an estimated 6.6% 12-month risk of developing major 
depressive disorder (MDD).7 Estimates for 12-month MDD prevalence among HIV+ adults 
range from 5% to 10%.8 A meta-analysis reported that the frequency of MDD diagnoses 
among HIV+ participants was nearly two times higher than the frequency among HIV- 
participants.9 Like HIV infection, MDD may also increase the risk for HF.10–13
Possible mechanisms for the association between HIV and HF include chronic inflammation 
and platelet activation.5 Similarly, depression is associated with autonomic nervous system 
dysregulation, inflammation, and platelet activation.14–16 It stands to reason that HIV+ 
adults with MDD may be at heightened risk for HF compared to the remaining population; 
however, to date, no studies have examined the risk of HF in individuals burdened with co-
occurring HIV and MDD.
Our objective, therefore, was to determine the association between HIV, MDD, and incident 
HF among a subset of HIV+ and HIV- veterans from the Veterans Aging Cohort Study 
(VACS) and to explore the effects of antidepressant use, HIV severity, and ART use on this 
association.
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Methods
Participants
Details of the prospective, longitudinal Veterans Aging Cohort Study (VACS) have been 
published previously.17 Since 1998, the VACS continually enrolled HIV+ and age-, sex-, 
race/ethnicity-, and geographic region-matched HIV- veterans in the same calendar year 
from the US Department of Veterans Affairs (VA) system. For this analysis, data from 
VACS participants alive and enrolled as of April 1, 2003 were extracted from the VA 
national electronic medical record system. The institutional review boards from the 
University of Pittsburgh, Yale University, and West Haven VA Medical Center approved 
this study.
Participants were included in this analysis if they were free of clinical CVD at baseline 
(April 1, 2003). Prevalent CVD at baseline was defined using International Classification of 
Diseases, Ninth Revision (ICD-9) codes for HF, acute myocardial infarction, unstable 
angina, stroke or transient ischemic attack, peripheral vascular disease, or cardiovascular 
revascularization on or before their baseline date. The final sample included 81,427 
Veterans (26,908 HIV+, 54,519 HIV-).
Independent Variables
Participants were considered HIV+ if they had at least one inpatient and/or two or more 
outpatient ICD-9 codes for HIV at baseline. The algorithm used to identify HIV+ veterans 
has high sensitivity (90%), specificity (99.9%), and positive predictive value (88%).17
Participants were considered to have MDD if at least one inpatient or two outpatient ICD-9 
codes for MDD (296.2x and 296.3x) identified in their electronic medical record beginning 
in 1998 (the earliest time point of available ICD-9 data in VACS) and up to the participant’s 
enrollment date in the VACS. Since 2000, the VA has promoted a strong screening, 
diagnosis and treatment program within the VA. Screening programs include the use of 
PHQ-2 instruments followed by clinical interviews in primary care and or referrals to 
primary care mental health clinics or specialty care (e.g., psychiatry) for confirmation of 
diagnosis and treatment. In a small study that compared MDD diagnoses made by general 
practitioners in primary care settings to Diagnostic and Statistical Manual of mental 
disorders, 4th edition (DSM-IV) criteria ranges for MDD, specificity was 89% while 
sensitivity was 79%.18 These findings were supported by a larger study that investigated the 
validity of billing diagnoses for clinical depression in electronic medical records.19
We categorized participants into four groups: HIV- without MDD (reference); HIV- with 
MDD; HIV+ without MDD; and HIV+ with MDD.
Dependent Variables
The primary outcome for this report, HF, was determined using VA and Medicare ICD-9 
codes (428.xx, 429.3, 402.11, 402.91, 425.x), a method shown to have a positive predictive 
value of 94.3%.20 The follow-up time for participants began from their first clinical 
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encounter on or after 4/1/2003 and continued until a HF event, death, or the last date of 
follow-up (12/31/2009).
Covariates
Our covariates were selected apriori based on our prior work and studies from others 
examining risk factors for heart failure. The Framingham Heart Study and others have 
identified risk factors for heart failure including age, hypertension, diabetes, smoking, 
cholesterol, body mass index, substance use, atrial fibrillation and flutter, and renal 
disease.4, 21–24 Administrative data were used to obtain age, sex, and race/ethnicity. 
Outpatient and laboratory reports from baseline visits stored in the VA medical record 
provided data regarding hypertension, diabetes mellitus, lipid concentrations, hemoglobin 
concentrations, renal function, atrial fibrillation, atrial flutter, alcohol abuse or dependence, 
cocaine abuse or dependence, and hepatitis C virus (HCV) infection. Baseline body mass 
index (BMI; kg/m2) and smoking status were acquired from health factor data collected by 
the VA and recorded in the VA medical record. Baseline antidepressant and HMG CoA 
reductase inhibitor (statin) data were obtained from VA pharmacy records.17
Three hypertension categories were used: none (blood pressure < 140/90 mmHg and no 
antihypertensive medication use); controlled (blood pressure < 140/90 mmHg and 
antihypertensive medication use); and uncontrolled (blood pressure ≥ 140/90 mmHg).25 
Diabetes mellitus diagnosis was determined using a combination of glucose levels, anti-
diabetes medication, and ICD-9 codes; an algorithm previously validated in the VACS.26 
Dyslipidemia was assessed using levels of low density lipoprotein cholesterol (LDL-c), high 
density lipoprotein cholesterol (HDL-c), and triglycerides measured in mg/dL. Statin use 
was determined within six months from enrollment. Anemia was based on hemoglobin 
concentrations (g/dL), and renal function was based on estimated glomerular filtration rate 
(eGFR; mL/min/1.73 m2). Alcohol abuse or dependence and cocaine abuse or dependence 
were measured based on ICD-9 codes.27 Hepatitis C virus infection was defined by one or 
more inpatient and/or two or more outpatient ICD-9 codes for a positive HCV antibody test 
result.28 Body mass index and smoking status (current, past, and never) were included in the 
VA electronic medical health record following prompts to the clinicians during patient 
visits. Obesity was defined as BMI ≥ 30 kg/m2. The smoking status reported in this health 
factor dataset has shown high agreement with self-reported smoking status on VACS-8 
surveys.29
Antidepressant use was defined as documentation of a filled prescription for selective 
serotonin reuptake inhibitor (SSRI), tricyclic antidepressant (TCA), or other antidepressant 
use from the VA pharmacy records during the baseline period (1998–2003). Medications 
were classified as “other” if they were in the following classes: tetracyclic antidepressant, 
monoamine oxidase inhibitor, serotonin-norepinephrine reuptake inhibitor, serotonin 
antagonist and reuptake inhibitor, norepinephrine reuptake inhibitor, norepinephrine-
dopamine reuptake inhibitor, and miscellaneous (Supplemental Table 1). Generic and brand 
names for antidepressants were used to search outpatient pharmacy records.
We included HIV-specific variables (CD4+ T-cell (CD4) counts, HIV-1 RNA, and ART 
use) for HIV+ participants from two time periods: baseline and recent.30 Baseline variables 
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were obtained during participant visits within 180 days of the baseline enrollment date 
(4/1/2003). Recent variables were obtained during the visit closest to HF, death, or the last 
follow-up date (12/31/2009). Antiretroviral medications were based on pharmacy data and 
categorized by drug class [i.e., nucleoside reverse-transcriptase inhibitors (NRTI), 
nonnucleoside reverse-transcriptase inhibitors (NNRTI), or protease inhibitors (PI)]. 
Additionally, four types of ART regimens were defined: NRTI with PI; NRTI with NNRTI; 
other regimen; and no ART use (reference). A previous study reported that 96% of HIV+ 
veterans obtain their ART medications through the VA system.17
Statistical analysis
Baseline descriptive statistics were calculated for each HIV/MDD group. T-tests (or non-
parametric counterpart) and chi-square tests were used to determine significant differences 
between the groups as appropriate. Incident HF diagnosis rates per 1000 person-years were 
calculated for each HIV/MDD group. Cox proportional hazards regression was used to 
model the association between HIV/MDD group and incident HF. We constructed three 
models: (1) unadjusted; (2) adjusted for demographics; and (3) adjusted for age, sex, race/
ethnicity, BMI, hypertension, diabetes mellitus, LDL-c, HDL-c, triglycerides, statin use, 
hemoglobin, renal function, atrial fibrillation, atrial flutter, smoking status, alcohol abuse or 
dependence, cocaine abuse or dependence, and HCV infection. The percent variance 
associated with each model is presented in Supplemental Table 2. We tested assumptions for 
Cox proportional hazard models using Schoenfeld residual plots. These plots did not show 
deviation from proportionality for our main exposure variable. Additional analyses 
examined this association among whites and African Americans separately. A Kaplan-Meier 
curve was created to display time to incident HF by the four HIV/MDD groups. Among 
those with MDD, HF incidence rates per 1000 person-years and adjusted hazard ratios were 
calculated by HIV status and antidepressant use. In a second analysis, we used Cox 
regression to model the association of MDD and incident HF among the HIV+ participants. 
This analysis included additional adjustments for baseline and recent CD4 counts, HIV-1 
RNA, and ART use. We included only participants with a diagnosis of MDD in our third 
analysis, which explored the association between antidepressant use and incident HF among 
HIV+ and HIV- participants.
Results
Within this cohort of 81,427 veterans, MDD prevalence was 17.0% overall and not 
significantly different between HIV+ and HIV- participants (18.8% vs. 16.1%, respectively). 
The four HIV/MDD groups made up the following proportions of the total sample: HIV- 
without MDD, 56.2%; HIV- with MDD, 10.8%; HIV+ without MDD, 26.8%; and HIV+ 
with MDD, 6.2%.
Baseline characteristics differed between the four HIV/MDD groups (Table 1). Regardless 
of MDD diagnosis, HIV+ participants were more likely than HIV- participants to have low 
HDL-c, high triglycerides, HCV infection, renal disease, anemia, and cocaine abuse or 
dependence and to be current smokers. However, HIV+ participants were less likely to have 
hypertension, diabetes, and high LDL-c and to be obese. Regardless of HIV status, 
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participants with MDD were more likely than participants without MDD to have diabetes, 
high triglycerides, HCV infection, cocaine abuse or dependence, and alcohol abuse or 
dependence; to be current smokers; and to use antidepressant medications (all with p < 
0.05).
During a median of 5.8 (25th-75th percentile: 3.3–6.6) years of follow-up, there were 2666 
incident HF events. The HF rate per 1000 person-years was significantly higher among HIV
+ participants with co-occurring MDD compared to rates in the other three groups, i.e. HIV- 
without MDD, HIV- with MDD, and HIV+ without MDD (Table 2).
After adjusting for traditional CVD risk factors, HIV- participants with MDD, HIV+ 
participants without MDD, and HIV+ participants with MDD had higher risk of incident HF 
than HIV- participants without MDD (Table 3). Age, hypertension, diabetes, low 
hemoglobin, low eGFR, atrial fibrillation, current smoking, cocaine abuse or dependence 
and HCV infection were independently associated with increased risk of incident HF. 
Hispanic race/ethnicity was associated with a lower risk of incident HF. When this model 
was additionally adjusted for SSRI, TCA, and other antidepressant use, the risk of HF 
remained elevated among HIV- participants with MDD (adjusted HF (aHR) = 1.17; 95% CI, 
1.02 – 1.34), HIV+ participants without MDD (1.28; 1.16 – 1.41), and HIV+ participants 
with MDD (1.64; 1.41 – 1.92) compared to the referent group. Importantly this association 
was present for whites and African Americans (Table 4). Moreover, when participants 
without MDD who were taking antidepressants were removed from the analysis, the HIV 
infected and depressed Veterans continued to have the highest risk of HF (HR 1.73; 1.47–
2.01). Participants with co-occurring HIV infection and MDD diagnosis had the poorest 
survival free of HF of all four groups (Figure 1). In separate analyses, we did not find a 
significant multiplicative interaction between HIV and MDD (p values>0.05).
We further explored incident HF risk in HIV- and HIV+ participants separately. MDD was 
associated with increased risk of HF in both groups (aHR = 1.21; 95% CI, 1.06 – 1.37 and 
1.29; 1.11 – 1.51, respectively). Among HIV+ participants, MDD remained a significant risk 
factor for HF after further adjusting for baseline traditional CVD risk factors, CD4 count, 
baseline HIV-1 RNA concentration, and ART regimen documented at the baseline visit 
(aHR = 1.30, 95% CI, 1.11 – 1.51). We found similar results when the model included; 
recent CD4 count, recent HIV-1 RNA concentration and recent ART regimen; or recent PI, 
NRTI, and NRTI use.
The majority of participants with MDD had at least one antidepressant prescription during 
the baseline period (90.2%). Among all participants in the sample with MDD, baseline 
antidepressant use was associated with fewer incident HF events, adjusting for HIV and 
cardiovascular disease risk factors (aHR = 0.76; 95% CI, 0.58 – 0.99). In a model that 
stratified the MDD participants by both HIV status and antidepressant use, the rates of 
incident HF were highest among HIV+ participants who did not use antidepressants (Table 
5).
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Discussion
Our findings indicate that both depression and HIV are associated with an increased risk of 
HF in veterans, even after adjusting for traditional CVD risk factors, comorbidities, and 
substance use. Participants with co-occurring HIV and MDD had the highest rates and risk 
of HF relative to those with only one of the conditions or neither condition. Furthermore, 
among HIV+ veterans, depression was associated with an increased risk of HF after 
additional adjustment for CD4 cell count, HIV-1 RNA levels, and ART use.
Our findings are consistent with previous studies reporting associations between (a) HIV 
and incident HF and (b) depression and incident HF in HIV- samples.4, 5, 13, 31 However, 
this study is the first to simultaneously examine HIV status, MDD diagnosis, and 
antidepressant use as predictors of incident HF in a large national cohort of HIV infected 
and uninfected people. In addition, our results are the first to suggest that MDD is an 
independent risk factor for HF in HIV+ adults. This finding is important as rates of incident 
HF among the HIV+ participants with depression in this cohort (~9 per 1000 person years) 
were higher than in the U.S. population (~2–5 per 1000 person years).32
The physiological mechanisms underlying the associations of HIV infection and depression 
with future HF have yet to be elucidated. With HIV infection, the risk of HF may be 
explained by vascular damage associated with the virus itself, chronic inflammation, lack of 
vascular repair due to CD4 cell depletion, or dyslipidemia following HIV infection or ART-
induced metabolic syndrome.4, 30, 33–35 With depression, possible mechanisms include 
alterations to the hypothalamic-pituitary-adrenal axis, dysregulation of the autonomic 
nervous system, chronic inflammation, and platelet activation.36, 37 In addition to these 
physiological changes, both HIV infection and depression are associated with unhealthy 
behavioral changes, such as substance use and decreased physical activity, which are risk 
factors for HF.38, 39
In this study, HIV+ participants with co-occurring MDD had the highest risk of HF. The 
Infectious Diseases Society of America has stressed the importance of recognizing 
depression in HIV+ patients.40 Our findings bolster this recommendation by adding another 
reason for doing so – i.e., depression as a potential risk factor for HF. In Table 4, we report 
preliminary evidence that raises the possibility that antidepressant use may decrease the 
excess risk for HF in HIV+ and HIV- adults. However, a prospective randomized controlled 
trial is needed to determine whether depression is a causal risk factor for HF and whether 
depression interventions reduce the risk of HF in the HIV infected and uninfected 
populations.41, 42
There are limitations of this study that warrant discussion. First, as our participants were 
predominantly men, the findings might not generalize to women. Second, HF and depression 
were based on ICD-9 codes. Therefore, some misclassification may have occurred (e.g., 
patients with true MDD or HF that was not indicated in their medical record with an ICD-9 
code), however, such misclassification would have biased our results to the null. Third, 
baseline depressive disorder diagnosis was used as a predictor. Depressive symptom severity 
tends to fluctuate over time, and previous findings suggest that the mean of symptom 
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severity assessed at multiple time points is a stronger predictor of subclinical CVD than 
depressive symptom severity assessed at one time point.43 However, because depressive 
episodes are likely to recur in those with a MDD diagnosis, a baseline measure of MDD 
diagnosis as we defined it should capture those at risk for chronic exposure to the unhealthy 
impact of depression.44, 45 Moreover, we did not assess whether “current” MDD (i.e., MDD 
within six months of and before baseline) was associated with HF because restricting the 
time window could lead to misclassification (i.e., participants who had been diagnosed with 
MDD but were not seen in clinic within six months before the baseline enrollment date 
would be classified as non-MDD). Lastly, our findings that depression treatment is 
associated with a reduced risk of HF among HIV+ veterans with MDD, while novel and 
intriguing, should be interpreted with caution. As this is an observational study and not a 
randomized control trial, we cannot eliminate confounding due to indication associated with 
the treatment of depression. Moreover, improved HF outcomes may be attributed to more 
frequent visits with a provider and better management of CVD risk factors and other 
medical conditions in addition to MDD treatment. Additionally, only 10% of participants 
with an MDD diagnosis did not have a prescription for an antidepressant during the baseline 
period. The high prevalence of treatment is likely a reflection of the fact that MDD in our 
study was determined by clinical diagnostic codes and not by a formal depression screening 
instrument administered to all participants. It is likely that some participants with 
unrecognized depression existed in our non MDD group. This possible misclassification, 
however, would lead us to underestimate the strength of the MDD-HF relationship, as 
veterans with unrecognized depression would be included in our referent group.
In conclusion, HIV and MDD are each associated with an increased risk of incident HF. 
HIV+ veterans with MDD had the highest rates of and risk for HF compared to veterans 
with either HIV, depression, or neither condition. These results suggest that MDD is a 
possible independent risk factor for HF among HIV+ patients and thus reinforce the 
importance of screening for and effectively managing depression in this patient population. 
Future studies in both HIV infected and uninfected adults should aim (a) to clarify the 
mechanisms underlying the depression-HF association and (b) to determine whether 
evidence-based depression treatment may help to reduce HF morbidity and mortality in 
these populations.
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Figure 1. 
Kaplan Meier Survival Curves for incident heart failure stratified by HIV and major 
depressive disorder status.
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Table 1
Baseline participant characteristics by major depressive disorder (MDD) diagnosis and HIV status (N = 
81,427)*
HIV-uninfected HIV-infected
No MDD MDD No MDD MDD
Characteristic (n= 45,728) (n= 8,791) (n= 21,850) (n= 5,058)
Age, years, mean (SD) 48.8 (9.5) 48.1 (7.4) 48.3 (9.7) 47.4 (7.9)
Male, % 97.5 95.6 97.7 95.3
Race / Ethnicity, %
    White 37.0 41.6 37.0 42.5
    African American 48.0 46.8 48.5 45.9
    Hispanic 7.5 9.2 6.9 8.2
    Other 7.4 2.4 7.7 3.4
Body Mass Index ≥ 30 kg/m2, % 38.7 38.6 13.7 16.6
Hypertension, %
    None 58.3 60.8 67.3 68.6
    Controlled 9.4 10.1 7.0 7.9
    Uncontrolled 32.4 29.0 25.7 23.6
Diabetes mellitus, % 20.0 23.1 13.3 16.1
Lipids, mg/dL, %
    LDL cholesterol < 100 31.2 33.5 46.2 46.5
    LDL cholesterol 100 – 129 33.3 33.4 29.7 29.6
    LDL cholesterol 130 – 159 23.2 21.1 15.9 15.7
    LDL cholesterol ≥ 160 12.3 12.0 8.2 8.1
    HDL cholesterol ≥ 60 15.0 13.4 11.1 10.2
    HDL cholesterol 40 – 59 47.7 45.5 38.0 37.2
    HDL cholesterol < 40 37.3 41.1 50.9 52.6
    Triglycerides ≥ 150 37.4 42.2 46.9 49.1
Statin use within 6 months of
enrollment, %
9.4 11.6 6.4 6.8
Hemoglobin, g/dL, %
    ≥ 14 73.1 70.9 55.1 57.1
    12 – 13.9 22.9 24.9 31.9 32.0
    10 – 11.9 3.2 3.5 9.5 8.5
    < 10 0.8 0.8 3.5 2.5
Renal function, mL/min/1.73 m2, %
    eGFR ≥ 60 95.3 95.9 93.6 94.6
    eGFR 30 – 59 4.2 3.7 5.2 4.4
    eGFR < 30 0.5 0.3 1.2 1.1
Atrial fibrillation, % 1.0 0.8 0.8 0.7
Atrial flutter, % 0.3 0.4 0.3 0.2
Smoking, %
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HIV-uninfected HIV-infected
No MDD MDD No MDD MDD
Characteristic (n= 45,728) (n= 8,791) (n= 21,850) (n= 5,058)
    Never 31.4 22.8 28.4 19.3
    Past 16.5 13.4 13.7 11.0
    Current 52.1 63.8 57.8 69.7
Alcohol abuse or dependence, % 10.5 27.5 10.8 28.1
Cocaine abuse or dependence, % 5.5 16.3 8.5 23.3
HCV infection, % 13.9 24.0 32.7 43.2
Antidepressant use, %‡
    Any SSRI use 20.4 73.7 22.8 73.6
    Any TCA use 11.3 25.3 14.7 29.2
    Any other antidepressants use† 20.6 70.4 22.2 68.2
    SSRI only use 8.0 14.1 9.8 14.8
    TCA only use 5.4 2.0 7.3 2.7
    Other antidepressants only use 8.4 10.9 9.2 10.6
No antidepressant medications 64.1 10.0 58.4 9.4
HIV-specific risk factors
CD4 cell count, mm3, %
    ≥ 500 at baseline … … 31.4 34.6
    200 – 499 at baseline … … 40.0 40.5
    < 200 at baseline … … 28.6 24.9
    ≥ 500 at recent visit … … 41.5 41.7
    200 – 499 at recent visit … … 39.2 38.4
    < 200 at recent visit … … 19.3 20.0
HIV-1 RNA, ≥ 500 copies/mL at
baseline, %
… … 55.1 56.5
HIV-1 RNA, ≥ 500 copies/mL at
recent visit, %
… … 24.5 26.4
ART use, %
    NRTI at baseline … … 48.3 49.6
    NNRTI at baseline … … 22.6 22.1
    PI at baseline … … 25.3 27.1
    NRTI at recent visit … … 73.7 68.1
    NNRTI at recent visit … …
    PI at recent visit … … 38.1 39.8
Regimen, %
    NRTI + PI at baseline … … 20.4 21.6
    NRTI + NNRTI at baseline … … 22.1 21.6
    Other at baseline … … 6.7 7.2
    No ART at baseline … … 50.9 49.6
    NRTI + PI at recent visit … … 32.4 34.1
    NRTI + NNRTI at recent visit … … 35.9 28.6
    Other at recent visit … … 8.3 8.6
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HIV-uninfected HIV-infected
No MDD MDD No MDD MDD
Characteristic (n= 45,728) (n= 8,791) (n= 21,850) (n= 5,058)
    No ART at recent visit … … 23.4 28.8
Abbreviations: ART, antiretroviral therapy; BMI, body mass index (calculated as kg/m2); eGFR, estimated glomerular filtration rate; HCV, 
hepatitis C virus; HDL, high-density lipoprotein; HIV, human immunodeficiency virus; LDL, low-density lipoprotein; MDD, major depressive 
disorder; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor; SSRI, 
selective serotonin reuptake inhibitors; TCA, tricyclic antidepressants
*All characteristics were significantly different between groups (p < 0.05) except atrial flutter (p = 0.201), recent CD4 cell counts (p = 0.492), 
baseline HIV-1 RNA concentration (p = 0.104), baseline NRTI use (p = 0.093), baseline NNRTI use (p = 0.436), and baseline ART regimens (p = 
0.080)
†See Supplemental Table for medications included in each antidepressant medication category
‡Any Antidepressant use refers to the proportion of Veterans in a category that were taking a class of antidepressant, regardless of whether they 
were on multiple medications. “Only use” refers to the proportion of Veterans who are only taking that one class of medication. “No medication” 
refers to the proportion of Veterans who were not on any of the classes of antidepressant medication.
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Table 2
Unadjusted rates of incident heart failure by major depressive disorder (MDD) diagnosis and HIV status (N = 
81,427)
HIV status /
MDD diagnosis
Number of
participants
Number of
HF events
Rates of HF per 1000 p-y
(95% CI)
HIV -- | No MDD 45,728 1,339 6.04 (5.73 – 6.38)
HIV -- | MDD 8,791 319 6.87 (6.16 – 7.67)
HIV + | No MDD 21,850 774 7.56 (7.05 – 8.11)
HIV + | MDD 5,058 234 9.32 (8.20 – 10.60)
Abbreviations: HF, heart failure; HIV, human immunodeficiency virus; MDD, major depressive disorder; p-y, person-years
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Table 3
Cox proportional hazard regression models examining the association between HIV/MDD group and incident 
heart failure
Characteristic Model 1
HR (95% CI)
Model 2
HR (95% CI)
Model 3
HR (95% CI)
HIV / MDD Group
    HIV -- | No MDD 1 [Reference] 1 [Reference] 1 [Reference]
    HIV -- | MDD 1.13 (1.00 – 1.27) 1.30 (1.15 – 1.47) 1.19 (1.05 – 1.35)
    HIV + | No MDD 1.25 (1.15 – 1.37) 1.32 (1.20 – 1.44) 1.28 (1.16 – 1.41)
    HIV + | MDD 1.54 (1.34 – 1.77) 1.87 (1.62 – 2.15) 1.68 (1.45 – 1.95)
Age, 10 year intervals 2.04 (1.96–2.12) 1.78 (1.70 – 1.86)
Female sex 1.00 (0.77–1.31) 1.01 (0.77 – 1.33)
Race / Ethnicity
    White 1[Reference] 1 [Reference]
    African American 1.34 (1.24–1.46) 1.05 (0.96 – 1.15)
    Hispanic 0.80 (0.68–0.95) 0.77 (0.65 – 0.92)
    Other 0.88 (0.73–1.07) 0.92 (0.76 – 1.11)
Body Mass Index ≥ 30 1.25 (1.14 – 1.36)
Hypertension
    None 1 [Reference]
    Controlled 1.78 (1.58 – 2.01)
    Uncontrolled 1.94 (1.77 – 2.12)
Diabetes mellitus 1.75 (1.61 – 1.91)
Lipids, mg/dL
    LDL cholesterol < 100 1 [Reference]
    LDL cholesterol 100 – 129 0.88 (0.79 – 0.98)
    LDL cholesterol 130 – 159 0.88 (0.78 – 1.00)
    LDL cholesterol ≥ 160 0.93 (0.78 – 1.12)
    HDL cholesterol ≥ 60 1 [Reference]
    HDL cholesterol 40 – 59 1.04 (0.90 – 1.21)
    HDL cholesterol < 40 1.04 (0.89 – 1.21)
    Triglycerides ≥ 150 1.00 (0.91 – 1.10)
Statin use within 6 months 1.08 (0.97 – 1.21)
Hemoglobin, g/dL
    ≥ 14 1 [Reference]
    12 – 13.9 1.32 (1.20 – 1.45)
    10 – 11.9 1.84 (1.58 – 2.14)
    < 10 2.23 (1.75 – 2.85)
Renal function, mL/min/1.73 m2
    eGFR ≥ 60 1 [Reference]
    eGFR 30 – 59 2.01 (1.78 – 2.28)
    eGFR < 30 5.21 (4.31 – 6.30)
Atrial fibrillation 2.15 (1.63 – 2.84)
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Characteristic Model 1
HR (95% CI)
Model 2
HR (95% CI)
Model 3
HR (95% CI)
Atrial flutter 1.59 (0.91 – 2.78)
Smoking
    Never 1 [Reference]
    Past 1.09 (0.96 – 1.23)
    Current 1.42 (1.29 – 1.57)
Alcohol abuse or dependence 0.98 (0.86 – 1.12)
Cocaine abuse or dependence 1.27 (1.09 – 1.48)
HCV infection 1.30 (1.19 – 1.43)
Model 1: HIV MDD only
Model 2: Model 1+ age, sex, race/ethnicity
Model 3: Model 2+ all covariates
Abbreviations: BMI, body mass index (calculated as kg/m2); eGFR, estimated glomerular filtration rate; HCV, hepatitis C virus; HDL, high-
density lipoprotein; HIV, human immunodeficiency virus; HR, hazard ratio; LDL, low-density lipoprotein; MDD, major depressive disorder
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Table 4
Cox proportional hazard regression models examining the association between HIV/MDD group and incident 
heart failure in Whites and African Americans
Whites* African Americans*
Characteristic HR (95% CI) P value HR (95% CI) P value
HIV / MDD Group
    HIV -- | No MDD 1.00 1.00
    HIV -- | MDD 1.25 (1.02, 1.53) 0.03 1.07 (0.90, 1.27) 0.46
    HIV + | No MDD 1.22 (1.04, 1.44) 0.02 1.27 (1.11, 1.45) <0.001
    HIV + | MDD 1.63 (1.28, 2.09) <0.001 1.71 (1.40, 2.09) <0.001
Abbreviations: HIV, human immunodeficiency virus; HR, adjusted hazard ratio; MDD, major depressive disorder
*All models for HF were adjusted for age, sex, body mass index, hypertension, diabetes mellitus, lipids, statin use, hemoglobin, renal function, 
atrial fibrillation, atrial flutter, smoking, alcohol abuse or dependence, cocaine abuse or dependence, and HCV infection
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